CHO Pharma (ROCO:6586) Marketable Securities: NT$2,008.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6586 CHO Pharma Inc ROCO:6586
25 GF Score
Price NT$113.00
! 4 Warning Signs
View Full Analysis

What is CHO Pharma Marketable Securities?

CHO Pharma ROCO:6586 +0.44% 25 Marketable Securities is NT$2,008.00 Mil as of Dec. 2025. GuruFocus rates ROCO:6586 with a GF Score™ of 25/100. The stock has 4 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. CHO Pharma's Marketable Securities for the quarter that ended in Dec. 2025 was NT$2,008.00 Mil.

CHO Pharma's annual Marketable Securities declined from Dec. 2023 (NT$2,398.90 Mil) to Dec. 2024 (NT$2,344.10 Mil) and declined from Dec. 2024 (NT$2,344.10 Mil) to Dec. 2025 (NT$2,008.00 Mil).

CHO Pharma  (ROCO:6586) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

CHO Pharma Marketable Securities Related Terms

CHO Pharma Marketable Securities Historical Data

* Premium members only.

The historical data trend for CHO Pharma's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CHO Pharma Marketable Securities Chart

CHO Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 538.90 538.90 2,398.90 2,344.10 2,008.00

CHO Pharma Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,398.90 2,371.90 2,344.10 2,058.00 2,008.00
ROCO:6586
25GF Score
CHO Pharma Inc ROCO:6586
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CHO Pharma Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of NT$2,008.00 Mil mean?
CHO Pharma (ROCO:6586) has a Marketable Securities of NT$2,008.00 Mil as of Dec. 2025. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on CHO Pharma and its competitors.
Is CHO Pharma's Marketable Securities too high?
CHO Pharma's current Marketable Securities is NT$2,008.00 Mil. Overall, CHO Pharma has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does CHO Pharma's Marketable Securities compare to VRTX and REGN?
CHO Pharma's Marketable Securities of NT$2,008.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on CHO Pharma and its competitors. CHO Pharma's current Marketable Securities is NT$2,008.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CHO Pharma stock overvalued right now?
CHO Pharma (ROCO:6586) has a current Marketable Securities of NT$2,008.00 Mil. The current Marketable Securities is NT$2,008.00 Mil. CHO Pharma's overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For CHO Pharma (ROCO:6586), the current Marketable Securities is NT$2,008.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CHO Pharma Business Description

Address Lane 130, Sec. 1 Academia Road, 7th Floor, Building C, No.99, Nangang, Taipei, TWN, 115202
CHO Pharma Inc is a biopharmaceutical company mainly focused on the development and commercialization of innovative products based on the proprietary glycan engineering technologies. It offers antibodies, such as CHO-H01, CHO-H02, CHO-A04 for cancer; CHO-H03, an antibody for autoimmune disease; CHO-S05 dual-effect anti-flu drugs; and CHO-V06 glycan-based vaccines and drugs.
25GF Score

Get the complete analysis for ROCO:6586

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$113.00
Price